1. Gilead Sciences Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ: GILD) takes the No. 1 spot because it combines an attractive valuation, a durable pharmaceutical franchise, limited near-term patent pressure and the largest implied upside to CFRA’s price target among the stocks in this ranking.
The biotechnology company has spent decades building one of the world’s strongest franchises in infectious disease.
Gilead Sciences, Inc. (NASDAQ: GILD) develops treatments across HIV/AIDS, hepatitis C, liver disease, hematology, oncology and inflammation. Its leading HIV medicines include Biktarvy, Descovy and Genvoya, giving the company an established presence in a therapeutic area where patients can remain on treatment for long periods.
That recurring nature of HIV treatment is important from an investment perspective.
Unlike a short-course medicine that a patient may use briefly, chronic treatments can create durable revenue streams when drugs maintain strong efficacy, safety and market share.
CFRA analyst Sel Hardy believes Gilead Sciences, Inc. (NASDAQ: GILD) is attractively valued relative to its growth outlook, and one detail makes the investment thesis particularly interesting: the company reportedly has no major commercial products facing loss of exclusivity until 2036.
Patent expirations are among the largest risks facing pharmaceutical investors, so a long runway before key exclusivity losses can provide management with valuable time to expand existing franchises and develop new ones.
The most exciting near-term catalyst may be Yeztugo.
The U.S. approval of Yeztugo as the first twice-yearly HIV prevention drug could represent an important development for HIV prevention. A medicine requiring dosing only twice per year could dramatically improve convenience compared with regimens that require much more frequent administration.
Convenience can become especially important in preventive medicine because adherence often determines how effective a treatment becomes in the real world.
Hardy projects approximately 5.5% full-year HIV revenue growth for Gilead Sciences, Inc. (NASDAQ: GILD) in 2026, suggesting that the company’s established franchise still has room to expand even before considering potential contributions from newer products.
Then there is valuation.
CFRA has a “buy” rating and a $170 price target for Gilead Sciences, Inc. (NASDAQ: GILD), while the stock closed at $131.28 on July 30. Based on those supplied figures, the target represents approximately 29.5% potential upside, easily the largest implied return among the 10 healthcare stocks in this countdown.
That does not guarantee Gilead Sciences, Inc. (NASDAQ: GILD) will rise nearly 30%. Analyst targets are estimates, not promises, and pharmaceutical companies remain exposed to clinical, competitive and regulatory risks.
But the gap is large enough to deserve attention.
The investment thesis also goes deeper than a single target price. Gilead Sciences, Inc. (NASDAQ: GILD) has an entrenched HIV franchise, a potentially important twice-yearly prevention treatment, years before major commercial products face exclusivity expiration and additional exposure to oncology and other therapeutic markets.
That creates an unusual combination of established cash-generating products and future optionality.
For investors searching for undervalued healthcare stocks, biotech stocks to buy, pharmaceutical stocks with upside and the best healthcare stocks for 2026, Gilead Sciences, Inc. (NASDAQ: GILD) arguably provides the most compelling balance of valuation and identifiable catalysts among the companies included here.
While Eli Lilly and Company (NYSE: LLY) may have the louder growth story and Merck & Co., Inc. (NYSE: MRK) owns one of the pharmaceutical industry’s greatest oncology franchises, Gilead Sciences, Inc. (NASDAQ: GILD) enters 2026 with something value-conscious investors may appreciate even more: expectations that still appear relatively reasonable compared with the opportunities ahead.
That is enough to give Gilead Sciences, Inc. (NASDAQ: GILD) the No. 1 position in this ranking of healthcare stocks to buy for 2026.
YOU MUST READ THIS: 10 Best Medicine Stocks That Could Make Investors 100% Richer
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
